Results 71 to 80 of about 3,283 (198)

Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases

Graefe's Archive for Clinical and Experimental Ophthalmology
Anti-vascular endothelial growth factor (VEGF) therapies have transformed the treatment of retinal diseases. However, VEGF signaling is only one component of the complex, multifactorial pathophysiology of retinal diseases, and many patients have residual
Varun Chaudhary, Florie Mar, Manuel J. Amador, Andrew Chang, Kara Gibson, Antonia M. Joussen, Judy E. Kim, Junyeop Lee, Philippe Margaron, Insaf Saffar, David T Wong, C. Wykoff, S. Sadda   +12 more
semanticscholar   +1 more source

Current and Emerging Pharmacologic Therapies for Diabetic Retinopathy

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 3, March 2026.
ABSTRACT Diabetic retinopathy, a prevalent microvascular complication of diabetes mellitus, is a leading cause of blindness among adults in developed countries. Risk factors include prolonged duration of diabetes, elevated glycosylated hemoglobin levels, hypertension, and dyslipidemia, with rapid glucose reduction also increasing risk for developing ...
Jennifer N. Clements, Julia Mesawich, Cassandra Twisdale   +2 more
wiley   +1 more source

Outcomes After Switching to Faricimab for Refractive Macular Edema in Treatment-Experienced Eyes with Neovascular Age-Related Macular Degeneration [PDF]

Yaqoob Qaseem,1 Kirk Kohwa Hou,1,2 Moritz S Pettenkofer1 1Retina Division, Stein Eye Institute, University of California Los Angeles, Los Angeles, CA, USA; 2Doheny Eye Institute, Los Angeles, CA, USACorrespondence: Moritz S Pettenkofer, Retina Division ...
Pettenkofer MS, Qaseem Y, Hou KK
core  

Severe Intraocular Inflammation Following Intravitreal Faricimab.

JAMA ophthalmology
Importance Monitoring for and reporting potential cases of intraocular inflammation (IOI) in clinical practice despite limited occurrences in clinical trials, including experiences with relatively new intravitreal agents, such as brolucizumab ...
Loka Thangamathesvaran, Jun Kong, S. Bressler, Mandeep Singh, Adam S. Wenick, Adrienne W. Scott, J. F. Arevalo, N. Bressler   +7 more
semanticscholar   +1 more source

Therapeutic effect of faricimab in macular telangiectasia type 1 and Coats’ disease: case series

BMC Ophthalmology
Background To report the anatomical and functional outcomes of intravitreal faricimab injection in cases of macular telangiectasia type 1 and Coats’ disease that were refractory to previous treatments.
Hyun Young Park, Kwangsic Joo, Se Joon Woo   +2 more
doaj   +1 more source

OCT angiography and structural biomarker outcomes of faricimab versus aflibercept in treatment-naïve polypoidal choroidal vasculopathy

Photodiagnosis and Photodynamic Therapy
Purpose: Comparative studies of faricimab and aflibercept 2 mg in polypoidal choroidal vasculopathy (PCV) have relied on conventional optical coherence tomography (OCT) biomarkers, leaving their effects on choriocapillaris perfusion uncharacterized.
Ai-Hua Hsieh, Sheng-Min Hsu, Chun-Hsiang Chang, Po-Chin Kuo, Kuan-Ying Chen, Yu-Kuei Lee   +5 more
doaj   +1 more source

Faricimab efficacy in type 1 macular neovascularization: AI-assisted quantification of pigment epithelium detachment (PED) volume reduction over 12 months in Naïve and switch eyes

International Journal of Retina and Vitreous
This study evaluates the efficacy of intravitreal Faricimab in reducing pigment epithelium detachment (PED) and fluid volumes in both treatment-naïve eyes and eyes unresponsive to anti-VEGF mono-therapies, all diagnosed with type 1 macular ...
Jennifer Cattaneo, P. Forte, Giovanni Forte, C. Eandi   +3 more
semanticscholar   +1 more source

Comparative efficacy and safety of Faricimab with other intravitreal anti-vascular endothelial growth factor in the treatment of Neovascular age related macular degeneration- A Systematic review and meta-analysis

Asian Journal of Medical Sciences
Age-related macular degeneration (AMD) is the leading cause of visual impairment in patients age 50 and older, with an estimated 200 million people affected worldwide.
Renuga Devi Kaliaperumal , Nandhini P, Reena Mohan , Nallamuthu P , Jenifer Florence Mary J   +4 more
doaj   +1 more source

Quantitative analysis of vitreous changes in intraocular inflammation following faricimab treatment in a real world setting

International Journal of Retina and Vitreous
Background To analyze the incidence, and clinical characteristics of intraocular inflammation (IOI) associated with faricimab in a tertiary center in Austria.
Clemens Thürridl, Konrad Dörfler, Jan Rothbächer, Markus Eidherr, Haidar Khalil, Josef Huemer, Matthias Bolz   +6 more
doaj   +1 more source

Efficacy and durability of GB10, a novel bispecific VEGF/Ang-2 neutralizing fusion protein, in ocular neovascularization models

Frontiers in Pharmacology
PurposeTo evaluate the preclinical efficacy, durability, and ocular biodistribution profiling of GB10, a novel bispecific vascular endothelial growth factor/angiopoietin 2 neutralizing fusion protein, compared with faricimab in models of choroidal and ...
Meiqi Hao, Qiongying You, Xiling Wei, Suofu Qin   +3 more
doaj   +1 more source